Which ticker should investors monitor for updates?

Investors should follow Torrent Pharmaceuticals Ltd on the BSE under ticker 500420. No NSE ticker was provided in the filing.

Earnings

16 July 2026 at 02:53 pm IST• 2 min read

Torrent Pharmaceuticals schedules board meeting to approve Q2 FY2026 unaudited results

The board will meet on 30 July 2026 to consider and approve the unaudited standalone and consolidated financial results (limited review) for the quarter ended 30 June 2026.

TORNTPHARMTorrent Pharmaceuticals Ltd

What Torrent Pharmaceuticals announced

Torrent Pharmaceuticals Ltd filed a notice with BSE on 16 July 2026 stating that its Board of Directors will convene on 30 July 2026. The sole agenda is to consider and approve the unaudited standalone and consolidated financial results (with limited review) for the quarter ended 30 June 2026.

"The meeting of the Board of Directors of the Company is scheduled on 30/07/2026, inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results (with limited review) for the quarter ended on 30‑Jun‑26."

No financial figures or performance metrics were disclosed in the intimation; the filing merely signals the timing of the board's approval process.

Board meeting details

Date of meeting: 30 July 2026
Purpose: Approval of unaudited standalone and consolidated results for Q2 FY2026 (quarter ended 30 June 2026).
Review level: Limited review, meaning the results have undergone a restricted audit scope rather than a full statutory audit.
Filing date: 16 July 2026, 09:23:49 UTC.
Exchange: BSE (ticker 500420). No NSE ticker was provided.

The company has not indicated any additional agenda items such as dividend declarations, board appointments, or capital actions.

Key facts at a glance

Detail	Value
Company	Torrent Pharmaceuticals Ltd
BSE ticker	500420
Filing date	16 July 2026
Board meeting date	30 July 2026
Period covered by results	Quarter ended 30 June 2026
Type of results	Unaudited (limited review)
Source	BSE corporate filing (PDF)

Why this matters for investors

The filing informs shareholders that the formal approval of the quarter’s financials is pending. Until the board signs off, the results remain unaudited, which may affect the level of assurance investors place on the numbers once released. A limited‑review approach typically speeds up reporting but provides a narrower scope of verification compared with a full audit. Investors should watch for the subsequent press release or filing that will disclose the actual figures and any commentary from management.

Conclusion

Torrent Pharmaceuticals has scheduled its board meeting for 30 July 2026 to approve the unaudited Q2 FY2026 results. The filing does not contain any financial data, and no further agenda items were disclosed. Stakeholders should await the post‑meeting announcement for the detailed results and any related management commentary.

Frequently asked questions

When will the Q2 FY2026 financial results be publicly released?

The filing only announces the board meeting on 30 July 2026 to approve the results. The company has not disclosed the exact release date; it is typically announced after the board’s approval.

What does ‘limited review’ mean for the unaudited results?

Limited review indicates that the financial statements have been examined by the auditors with a restricted scope, providing less assurance than a full statutory audit but allowing faster reporting.

Are any financial figures disclosed in this filing?

No. The intimation contains no revenue, profit, or other monetary figures for the quarter ended 30 June 2026.

Is there any dividend or share‑buyback agenda attached to the meeting?

The filing does not mention any dividend declaration, share buy‑back, or other corporate actions; the sole agenda is approval of the unaudited results.

Related stocks

TORNTPHARMTorrent Pharmaceuticals Ltd

Source filing: view original